Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexClinical trial evidence has indicated that there may be serious side effects associated with taking Celebrex at higher doses. On December 17, 2004, Pfizer issued a Celebrex warning announcing that Celebrex users might be at increased health risks. A National Cancer Institute study that was conducted to measure the effects of Celebrex use for colorectal cancer prevention found that patients taking 400 to 800 milligram doses were at a greater risk of cardiovascular complications. Clinical trial participants taking these levels of Celebrex were found to be two and a half times more likely to suffer serious heart attack or stroke as a result of this popular pain medication.
After the announcement of this serious Celebrex warning, the manufacturers of this COX-2 selective non-steroidal anti-inflammatory drug (Pfizer), issued statements regarding how they plan to respond to this new trial evidence. Pfizer has promised to take immediate steps to understand and communicate the details of this Celebrex warning. Despite the Celebrex warning, Pfizer has stated that they do not plan to pull Celebrex off the market. Though Celebrex has not been recalled, this blockbuster drug is taking huge hits in sales as doctors and patients are deterred by these new Celebrex warning statements.
Celebrex is a prescription drug that was approved by the FDA in 1999 to treat the pain associated with osteoarthritis, rheumatoid arthritis, severe menstrual cramping and other chronic pain conditions. Prior to the recent Celebrex warning, this analgesic was the tenth most popular prescription drug creating annual revenue that exceeded two and a half billion dollars. Since the Celebrex warning was issued new prescription sales of Celebrex have dropped by fifty-six percent.
Reactions to the Celebrex warning have several implications for regulators, researchers, physicians, and patients around the world. In response to the Celebrex warning, the FDA is urging doctors and patients to limit their use of this medication and consider alternative treatment options until the exact nature and extent of this Celebrex warning is understood. Some university researchers have urged people currently participating in clinical trials involving Celebrex to stop taking the medication until Celebrex safety is better understood. The National Institutes of Health has ordered a review of at least forty agency-supported Celebrex clinical trials in an effort to better understand the Celebrex warning regarding long term cardiovascular safety.
The Celebrex warning has also generated lawsuit prospects against Pfizer for failing to adequately inform the public about the potential serious side effects that may be caused by Celebrex use. One such class action lawsuit has been filed on behalf of patients who have taken Celebrex but have not suffered injury. Because of the Celebrex warning and the failure of the pharmaceutical company to inform patients of these risks, this lawsuit seeks money for periodic medical testing of Celebrex users to detect and treat any potential health complications early. If you are concerned about the Celebrex warning, you may wish to speak to your doctor and contact a qualified attorney who can advise you of your legal rights and options with regards to the Celebrex warning.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...